Hydrogen gas inhalation therapy may not work sufficiently to mitigate oxidative stress induced with REBOA.
Yosuke Matsumura, Yosuke Hayashi, Makoto Aoki, Yoshimitsu Izawa · Scientific reports · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In an animal model, hydrogen gas inhalation therapy exhibited no significant difference compared to the control group in survival, lactate level, 8-OHdG, and intestinal mucosal injury following REBOA in a hemorrhagic shock model. These results are preclinical and add to understanding of how molecular hydrogen affects the condition studied. Further human research is needed to determine its clinical relevance.
How Molecular Hydrogen Was Used
In an animal model, this study investigated hydrogen gas inhalation therapy's potential to mitigate post-REBOA ischemia-reperfusion injuries (IRIs). 2% hydrogen gas inhalation was started simultaneously with REBOA inflation in the hydrogen group. Survival analysis showed no significant differences between the two groups (control vs. hydrogen, 4/5 vs.
What the Researchers Found
Hydrogen gas inhalation therapy exhibited no significant difference compared to the control group in survival, lactate level, 8-OHdG, and intestinal mucosal injury following REBOA in a hemorrhagic shock model.
Authors’ Conclusion
These results are preclinical and add to understanding of how molecular hydrogen affects the condition studied. Further human research is needed to determine its clinical relevance.